• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    12/20/24 4:30:35 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email
    false 0001948455 0001948455 2024-12-16 2024-12-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 16, 2024

     

    Ispire Technology Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41680   84-5106049
    (State or other jurisdiction of   (Commission file number)   (IRS Employer
    incorporation or organization)     Identification No.)

     

    19700 Magellan Drive

    Los Angeles, CA 90502

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (310) 742-9975

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ISPR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    Ispire Technology Inc. (the “Company”) was notified that on November 1, 2024 CBIZ CPAs P.C., previously known as Mayer Hoffman McCann P.C., purchased substantially all of the attest business assets of Marcum LLP (“Marcum”), the Company’s independent registered public accounting firm. Substantially all of the partners and staff that provided attestation services with Marcum joined CBIZ CPAs P.C. Marcum resigned as auditors of the Company effective December 16, 2024, and with the approval of the Audit Committee of the Company’s Board of Directors, on December 17, 2024, CBIZ CPAs P.C. was engaged as the Company’s independent registered public accounting firm for the fiscal year ended June 30, 2025, effective immediately, subject to ratification by the Company’s stockholders at the Company’s annual meeting of stockholders.

     

    The report of Marcum regarding the Company’s financial statements for the fiscal year ended June 30, 2024 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles except that the report included an explanatory paragraph regarding the adjustments described in Note 2 to the consolidated financial statements that were applied to restate the financial statements as of and for the year ended June 30, 2023 to correct misstatements. Marcum was not engaged to audit, review, or apply any procedures to the financial statements of the Company as of or for the year ended June 30, 2023 other than with respect to such adjustments and, accordingly, Marcum does not express an opinion or any other form of assurance on the June 30, 2023 financial statements taken as a whole.

     

    During the year ended June 30, 2024 and during the interim period from the end of the most recently completed year through December 16, 2024, the date of resignation, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to such disagreement in its report or (b) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), except that there were material weaknesses in the Company’s internal control over financial reporting reported by the Company on its Annual Report on Form 10-K for the year ended June 30, 2024 related to (1) the lack of controls to record assets acquired from a controlling stockholder in accordance with GAAP; (2) the lack of controls needed to enable us to evaluate significant estimates, including (i) the sufficiency of inventory reserve for slow-moving inventories and (ii) the credit loss history and use it to evaluate the sufficiency of credit loss reserve for accounts receivable under the Topic 326; (3) the lack of comprehensive accounting policies and procedures manual in accordance with U.S. GAAP and SEC reporting, including IT general controls, and a financial risk assessment to evaluate controls; and (4) the lack of a sufficient complement of personnel with appropriate technical expertise to evaluate complex accounting matters, resulting in the need to restate our unaudited financial statements as of and for the six months ended December 31, 2022 and the nine months ended March 31, 2023; the audited financial statements for the annual period ended June 30, 2023; and the unaudited financial statements for the three months ended September 30, 2023, the six months ended December 31, 2023, and the nine months ended March 31, 2024.

     

    Prior to engaging CBIZ CPAs P.C., the Company did not consult with CBIZ CPAs P.C. regarding the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by CBIZ CPAs P.C. on the Company’s financial statements, and CBIZ CPAs P.C. did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any such accounting, auditing or financial reporting issue.

     

    The Company provided Marcum with a copy of this Current Report on Form 8-K prior to its filing with the U.S. Securities and Exchange Commission (the “SEC”) and requested that Marcum furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter, dated December 19, 2024, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d)  Exhibits.

     

    The following exhibits are being filed with this Current Report on Form 8-K:

     

    Exhibit No.   Description
    16.1   Letter from Marcum LLP dated December 19, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Ispire Technology Inc.
         
      By: /s/ Michael Wang
        Name:  Michael Wang
        Title: Co-Chief Executive Officer
         
    Dated: December 20, 2024    

     

     

    2

     

     

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO and Secretary Pryzbyla Steven P. sold $29,592 worth of shares (9,000 units at $3.29), decreasing direct ownership by 2% to 390,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/17/26 5:53:18 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fargis John sold $14,625 worth of shares (7,500 units at $1.95), decreasing direct ownership by 16% to 39,099 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    11/24/25 4:30:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $45,001 worth of shares (17,046 units at $2.64), decreasing direct ownership by 4% to 399,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    10/2/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions

    Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions.

    2/4/26 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care